MedPath

Analgesia for Insertion of Intrauterine Contraception

Phase 3
Completed
Conditions
Insertion of Intrauterine Contraception
Interventions
Drug: Placebo
Registration Number
NCT02078063
Lead Sponsor
Karolinska Institutet
Brief Summary

Use of long acting reversible contraception (LARC) such as implants or intrauterine contraception (IUC) has been shown to reduce repeat abortions. LARCs have the advantage of being independent of user error and are considered to be underused, especially among young individuals where oral methods have high rates of user failure. IUC is often underused in young or nulliparous women due to fear of pain at insertion.

10 ml of mepivacaine (10mg/ml) or 10ml of sodium hydrochloride will be injected into the uterine cavity through a hydrosonography catheter before the tenaculum has been applied but prior to sounding and to insertion of the IUC.

The investigators' hypothesis is that instillation of 10 ml (10mg/ml) mepivacaine though a hydrosonography catheter prior to any instrument placement will provide more effective pain relief than instillation of 10 ml placebo (sodium chloride 9mg/ml).

Primary objective: To evaluate the difference in pain score at the time of the insertion of the IUC between treatment and control group.

Secondary objectives: To evaluate acceptability of the procedure.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
86
Inclusion Criteria
  • over 18 years of age and
  • opting for IUC for contraception
  • with a negative pregnancy test
  • willing to participate in the study after it has been explained orally and in written
Exclusion Criteria
  • previous conisation,
  • known cervical stenosis,
  • signs of ongoing genital infection,
  • known uterine abnormality,
  • any condition resulting in bleeding disorder or contraindication to any local anestetic will be excluded

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
NaCLPlacebo10 ml NaCl 9mg/ml instilled into the uterus through a hydrosonography catheter
MepivacaineMepivacaine10 ml of Mepivacaine for injection (Carbocain®) 10 mg/ml instilled into the uterus through a hydrosonography catheter
Primary Outcome Measures
NameTimeMethod
painOn day of insertion

difference in pain score (VAS)at the time of the insertion of the IUC between treatment and control group.

Secondary Outcome Measures
NameTimeMethod
Acceptability30 minutes after insertion

They will be asked if the would opt to have this type of pain relief were the ever to insert a new IUC (yes/no), if they would recommend this type of pain relief to any other women (yes/no) and to state how the procedure was compared to their expectations (worse/as expected/better).

Trial Locations

Locations (2)

Dept of Obstetrics and Gynecology, Danderyd Hospital

🇸🇪

Stockholm, Sweden

Upplands Väsby Ungdomsmottagning

🇸🇪

Stockholm, Sweden

© Copyright 2025. All Rights Reserved by MedPath